November 23, 2022 4:54pm

Gotta go, be safe in any holiday endeavor

Earnings: Mesoblast (MESO) a net loss for Q1/23 of -$16.9 million or -$2.43 per share and a cash position of $85.5 million and a runway to Q1/24

News: uniQure NV (QURE +$3.36 or +14.61% to $26.36) and Carlisle Companies (CSL +$0.07 to $255.63) the FDA approved the most expensive drug ever — a hemophilia gene therapy however, the $3.5 million price tag is ahead of a recommendation by the Institute for Clinical and Economic Review. <see IBD below link>

It’s an honor to be considered the “canary in the (sector) coal mine”! It’s more than opinion, the facts and truth need to be recognized!

Ask yourself, do you know why you own certain cell and gene therapy sector equities?

Why do I keep writing this blog/newsletter; to inform investors, what others won’t say or write

If I have learned one thing as a former research analyst in a venture and public fund now a journalist; it is that your life and your bank account are largely tied to your knowledge of price movements and questioning pricing targets.

 

The Dow closed UP +95.96 points (+0.28%), the S&P close UP +23.69 points (+0.59%) while the Nasdaq closed UP +110.91 points (+0.99%)

 

Henry’omics:

We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed higher Wednesday in a choppy session as meeting minutes from the Fed is looking to hand out … smaller rate hikes…  in the coming months as inflation cools off.

Any news that could shift the narrative around rate hikes going forward is important to markets, which are also seeing thin trading volume due to the holiday-shortened week. <CNBC>

The stock market will be closed on Thursday for the Thanksgiving holiday and will close early on Friday.

Economic Data Docket: Jobless claims data came into its highest level since August than expected at 240,000 for the week ending Nov. 19 where economist expected 225,000, signaling that the labor market may be weakening. At the same time, however, durable goods orders for October were stronger than anticipated, coming in at 1%, more than the 0.5% expected.

 

News (continued) UniQure NV (QURE): the infusion is approved for hemophilia B patients currently on a prevention regimen called Factor IX therapy, or who have a history of potentially deadly hemorrhages or serious bleeding episodes. At a one-time cost of $3.5 million, Carlisle and UniQure hope the drug is a cure. 

 

Wednesday’s … RegMed Investor’s (RMi) Pre-Open: “time to travel defensively while awaiting Fed minutes. Forget portfolio, safety is the focus to holiday remainder of week” … https://www.regmedinvestors.com/articles/12713

 

RegMed/Stem/Cell and Gene Therapy’s 35 covered equities’ Advance/Decline (A/D) lines: what happened

  • Wednesday’s advance/decline line opened positive at 25 up/ 7 down and 3 flats, stayed positive with 22 up/ 12 down and 1 flat at the mid-day, ending with a positive close of 22/12 and 1 flat.
  • Tuesday’s advance/decline line opened negative at 11 up/ 20 down and 4 flats, flipped positive with 17 up/ 16 down and 2 flats at the mid-day, ending with a positive close of 26/7 and 2 flats.
  • Monday’s advance/decline line opened negative at 11 up/ 23 down and 1 flat, stayed negative with 5 up/ 30 down and 0 flat at the mid-day, ending with a negative close of 4/31 and 0 flat.

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was down -0.37% and the XBI was up +0.04%
  • Tuesday, the IBB was up +0.79% and the XBI was up +1.38%
  • Monday, the IBB was down -0.55% and the XBI was down -1.36%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.94 points or -4.42% at 20.35
  • Tuesday was down -1.07 points or -4.79% at 21.29
  • Monday was down -0.77. points or -3.33% at 22.35

 

Q4 – November

  • Wednesday closed positive with 22 incliner, 12 decliners and 1 flat
  • Tuesday closed positive with 26 incliner, 7 decliners and 2 flats
  • Monday closed negative with 4 incliner, 31 decliners and 0 flats

 

The BOTTOM LINE: I try to keep it simple … and short!

Been also on a bit of a vacation - still writing and busy with "other" issues.

Thanksgiving comes tomorrow – escaping to a duck along with usual vegetables accoutrements, apple pie (which I had to taste already – for safety reasons) also with a pumpkin cheese cake, my way of saying “thanks” – a “yummy tummy”.

Amid the ongoing cell and gene therapy sector volatility, “our” universe’s trend remains " in a constant correction." That means that … lately we are investors are safer on the sidelines.

As I continually question, “The real question that should be asked is how many companies are at the end of sentiments …  leash?

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.